Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming Jones Las Vegas Healthcare and Technology Innovation Conference. The event will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas.
Mike Catelani, President and CFO of Anixa, is scheduled to present on April 9, 2025, at 4:30 PM PT. The presentation will be accessible via webcast, and Catelani will be available for one-on-one meetings throughout the conference.
The two-day conference, organized by Jones with B2i Digital's marketing support, will facilitate direct interactions between company executives and institutional investors through various formats including one-on-one meetings, fireside chats, panels, presentations, and networking events.
Anixa Biosciences (NASDAQ: ANIX), un'azienda biotecnologica specializzata nel trattamento e nella prevenzione del cancro, ha annunciato la sua partecipazione alla prossima Jones Las Vegas Healthcare and Technology Innovation Conference. L'evento si svolgerà il 8-9 aprile 2025, presso il The Venetian Resort di Las Vegas.
Mike Catelani, Presidente e CFO di Anixa, è programmato per presentare il 9 aprile 2025, alle 16:30 PT. La presentazione sarà accessibile tramite webcast e Catelani sarà disponibile per incontri individuali durante tutta la conferenza.
La conferenza di due giorni, organizzata da Jones con il supporto marketing di B2i Digital, faciliterà interazioni dirette tra i dirigenti aziendali e gli investitori istituzionali attraverso vari formati, tra cui incontri individuali, conversazioni informali, panel, presentazioni ed eventi di networking.
Anixa Biosciences (NASDAQ: ANIX), una empresa biotecnológica especializada en el tratamiento y la prevención del cáncer, ha anunciado su participación en la próxima Jones Las Vegas Healthcare and Technology Innovation Conference. El evento se llevará a cabo del 8 al 9 de abril de 2025, en The Venetian Resort en Las Vegas.
Mike Catelani, Presidente y CFO de Anixa, está programado para presentar el 9 de abril de 2025, a las 16:30 PT. La presentación será accesible a través de una transmisión en línea, y Catelani estará disponible para reuniones individuales durante toda la conferencia.
La conferencia de dos días, organizada por Jones con el apoyo de marketing de B2i Digital, facilitará interacciones directas entre los ejecutivos de la empresa y los inversores institucionales a través de varios formatos, incluyendo reuniones individuales, charlas informales, paneles, presentaciones y eventos de networking.
Anixa Biosciences (NASDAQ: ANIX), 암 치료 및 예방을 전문으로 하는 생명공학 회사가 다가오는 Jones Las Vegas Healthcare and Technology Innovation Conference에 참여한다고 발표했습니다. 이 행사는 2025년 4월 8-9일에 라스베가스의 The Venetian Resort에서 열릴 예정입니다.
Mike Catelani, Anixa의 사장 겸 CFO는 2025년 4월 9일 오후 4:30 PT에 발표할 예정입니다. 발표는 웹캐스트를 통해 접근 가능하며, Catelani는 컨퍼런스 기간 동안 일대일 미팅을 위해 자리를 마련할 것입니다.
이틀 동안 진행되는 컨퍼런스는 B2i Digital의 마케팅 지원으로 Jones에 의해 조직되며, 다양한 형식을 통해 기업 경영진과 기관 투자자 간의 직접적인 상호작용을 촉진할 것입니다. 여기에는 일대일 미팅, 파이어사이드 채팅, 패널, 발표 및 네트워킹 이벤트가 포함됩니다.
Anixa Biosciences (NASDAQ: ANIX), une entreprise de biotechnologie spécialisée dans le traitement et la prévention du cancer, a annoncé sa participation à la prochaine Jones Las Vegas Healthcare and Technology Innovation Conference. L'événement se tiendra les 8 et 9 avril 2025, au The Venetian Resort à Las Vegas.
Mike Catelani, Président et CFO d'Anixa, doit présenter le 9 avril 2025 à 16h30 PT. La présentation sera accessible par webcast, et Catelani sera disponible pour des réunions individuelles tout au long de la conférence.
La conférence de deux jours, organisée par Jones avec le soutien marketing de B2i Digital, facilitera les interactions directes entre les dirigeants d'entreprise et les investisseurs institutionnels à travers divers formats, y compris des réunions individuelles, des discussions informelles, des panels, des présentations et des événements de réseautage.
Anixa Biosciences (NASDAQ: ANIX), ein Biotechnologieunternehmen, das sich auf die Behandlung und Prävention von Krebs spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jones Las Vegas Healthcare and Technology Innovation Conference angekündigt. Die Veranstaltung findet am 8.-9. April 2025 im The Venetian Resort in Las Vegas statt.
Mike Catelani, Präsident und CFO von Anixa, wird am 9. April 2025 um 16:30 Uhr PT präsentieren. Die Präsentation wird über einen Webcast zugänglich sein, und Catelani wird während der gesamten Konferenz für persönliche Gespräche zur Verfügung stehen.
Die zweitägige Konferenz, organisiert von Jones mit Unterstützung von B2i Digital im Marketing, wird direkte Interaktionen zwischen Unternehmensführern und institutionellen Investoren durch verschiedene Formate wie persönliche Treffen, Kamin-Gespräche, Podiumsdiskussionen, Präsentationen und Networking-Events erleichtern.
- None.
- None.
Mike Catelani, President and CFO of Anixa, will deliver a presentation and be available for one-on-one meetings during the conference.
Details of the presentation are as follows:
Event: Jones Healthcare and Technology Innovation Conference
Date: April 9, 2025
Time: 4:30 PM PT
Location: The Venetian Resort
Webcast: https://wsw.com/webcast/jones2/anix/1888272
The Jones Healthcare and Technology Innovation Conference will bring together a select group of innovative companies and institutional investors for a two-day event. The conference will be focused on one-on-one (1x1) meetings, fireside chats, panels, presentations, and signature networking events. Organized by Jones, with marketing support from B2i Digital, Inc., the event offers an opportunity for direct dialogue between senior company executives and investors seeking engagement with innovative management teams.
For more information, a list of participating companies and to submit registration requests about the Jones Las Vegas Healthcare and Technology Innovation Conference, visit their B2i Digital Featured Conference page.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-jones-las-vegas-healthcare-and-technology-innovation-conference-on-april-9th-302416136.html
SOURCE Anixa Biosciences, Inc.
FAQ
When and where is Anixa Biosciences (ANIX) presenting at the Jones Healthcare Conference?
How can investors watch Anixa's (ANIX) presentation at the Jones Conference?
What types of activities will be featured at the Jones Healthcare Conference where ANIX is presenting?
Who is representing Anixa Biosciences (ANIX) at the Jones Healthcare Conference 2025?
